First Patient Dosed In Kronos Bio's KB-0742, In An Expansion Cohort Focused On Platinum-Resistant High-Grade Serous Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort for its drug KB-0742, targeting platinum-resistant high-grade serous ovarian cancer. The company plans to provide an efficacy update in the first half of 2025.
July 23, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kronos Bio has initiated dosing in an expansion cohort for its drug KB-0742, targeting a specific type of ovarian cancer. An efficacy update is expected in the first half of 2025.
The initiation of dosing in a new cohort for KB-0742 is a significant milestone for Kronos Bio, indicating progress in their clinical trials. The expected efficacy update in 1H 2025 could provide further positive news, potentially boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100